RxDoctor Payments Data

Linda Tharp

Optometrist · Memphis, TNNPI 1053302331

Payments from drug & device makers

$4,444in general payments, 2019–2025

Across 76 payments — averaging $58.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bausch & Lomb Americas Inc.$796
  • Mallinckrodt Hospital Products Inc.$397
  • Glaukos Corporation$265
  • Sight Sciences, Inc.$252
  • Harrow Eye, LLC$235
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,34498%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,444 in reported general payments places this provider in the 90th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$28,682
Medicare patients
157
Services billed
2,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine181$202,780
XiidraLifitegrast87$98,618
LumiganBimatoprost143$79,068
Cyclosporine98$73,837
Restasis MultidoseCyclosporine20$16,853
CombiganBrimonidine Tartrate/Timolol35$14,916
Alphagan PBrimonidine Tartrate31$12,155
Brimonidine Tartrate64$6,229
Travoprost20$3,794
Latanoprost229$3,410
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$3,159
Prednisolone Acetate17$702
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat13$244
Dorzolamide Hcl11$237
ErythromycinErythromycin Base20$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan, Alphagan P$1,227$325,773410 claims
Bausch & Lomb Americas Inc.Xiidra$796$98,61887 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →